These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31588817)

  • 1. Hypereosinophilic syndromes in the precision medicine era: clinical, molecular aspects and therapeutic approaches (targeted therapies).
    Iurlo A; Cattaneo D; Gianelli U
    Expert Rev Hematol; 2019 Dec; 12(12):1077-1088. PubMed ID: 31588817
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of Hypereosinophilic Syndromes.
    Roufosse F
    Immunol Allergy Clin North Am; 2015 Aug; 35(3):561-75. PubMed ID: 26209900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
    Williams AK; Dou C; Chen LYC
    Br J Haematol; 2021 Dec; 195(5):669-680. PubMed ID: 34105142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB; Sheikh J; Singh A
    Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic Agents for the Treatment of Hypereosinophilic Syndromes.
    Kuang FL; Klion AD
    J Allergy Clin Immunol Pract; 2017; 5(6):1502-1509. PubMed ID: 29122152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical management of the hypereosinophilic syndromes.
    Cogan E; Roufosse F
    Expert Rev Hematol; 2012 Jun; 5(3):275-89; quiz 290. PubMed ID: 22780208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel therapies for hypereosinophilic syndromes.
    Antoniu SA
    Neth J Med; 2010 Aug; 68(1):304-10. PubMed ID: 20739727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hypereosinophilic syndromes--the first 100 years.
    Butterfield JH; Weiler CR
    Semin Hematol; 2012 Apr; 49(2):182-91. PubMed ID: 22449628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hypereosinophilic syndromes].
    Groh M; Lefèvre G; Ackermann F; Étienne N; Kahn JE
    Rev Prat; 2019 Sep; 69(7):767-773. PubMed ID: 32233322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib for the treatment of hypereosinophilic syndromes.
    Helbig G
    Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How I treat hypereosinophilic syndromes.
    Klion AD
    Blood; 2015 Aug; 126(9):1069-77. PubMed ID: 25964669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal Manifestations of Hypereosinophilic Syndromes and Mast Cell Disorders: a Comprehensive Review.
    Nanagas VC; Kovalszki A
    Clin Rev Allergy Immunol; 2019 Oct; 57(2):194-212. PubMed ID: 30003499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?
    Iurlo A; Cattaneo D
    Blood Rev; 2023 Mar; 58():101014. PubMed ID: 36153195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies.
    Gotlib J
    Curr Opin Hematol; 2010 Mar; 17(2):117-24. PubMed ID: 20071982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib Treatment in PDGFRA-Negative Childhood Hypereosinophilic Syndrome.
    Weyand AC; Yanik GA; Bailey NG; Wu YM; Mody RJ; Castle VP
    Pediatr Blood Cancer; 2016 Jan; 63(1):164-7. PubMed ID: 26257279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
    Lierman E; Cools J
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1295-304. PubMed ID: 19761433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.